// App-Quantinova.ai

: Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study

Researchers

Presenter

  • Marius M. Hoeper

Principal Investigators

  • Hikmet Al-Hiti

  • Raymond L. Benza

  • Sung-A Chang

  • Paul A. Corris

  • Simon Gibbs

  • Ekkehard Grünig

  • Pavel Jansa

  • James R. Klinger

  • David Langleben

  • Vallerie V. Mclaughlin

  • Gisela Meyer

  • Jaquelina S. Ota-Arakaki

  • Andrew Peacock

  • Tomás Pulido

  • Stephan Rosenkranz

  • Dario Vizza

  • Anton Vonk-Noordegraaf

  • James White

  • Mikyung Chang

  • Frank Kleinjung

  • Christian Meier

  • Karen Paraschin

  • Gérald Simonneau

Medical Centers

  • Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany

  • University of Giessen and Marburg Lung Center member of the German Center of Lung Research DZL, Giessen, Germany

  • Departmant of Pathology, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic

  • The Ohio State University, Columbus, United States of America

  • Division of Cardiology, Department of Medicine, Cardiovascular Imaging Center, Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

  • National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital, London, United Kingdom

  • Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany

  • Clinicial Department of Cardiology and Angiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

  • Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI

  • Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada,

  • Department of Radiology, University of Michigan, Ann Arbor, United States of America

  • Centro de Hipertensão Pulmonar, Complexo Hospitalar Santa Casa de Porto Alegre,, Porto Alegre, Brazil

  • Pulmonary Circulation Group, Department of Medicine, Universidade Federal de São Paulo - Hospital São Paulo, São Paulo, Brazil

  • Scottish Pulmonary Vascular Unit, Regional Lung and Heart Centre, Glasgow, United Kingdom

  • Cardiopulmonary Department, National Heart Institute, Mexico City, Mexico

  • Clinic III for Internal Medicine (Cardiology, and Centre for Molecular Medicine Cologne (CMMC, University of Cologne, Cologne, Germany

  • Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • University of Rochester Medical Center, Rochester, New York, United States

  • Bayer, Berlin, Germany

  • Bayer SA, Sao Paulo, Brazil

  • Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France,

Locations

  • Germany

  • Czech Republic

  • United States

  • Republic of South Korea

  • United Kingdom

  • Canada

  • Brazil

  • Mexico

  • Italy

  • Netherlands

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • IV

Study Id's

  • NCT02891850

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved